Cargando…

Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

AIM: Associations between antinuclear antibodies (ANAs) and disease severity in nonalcoholic fatty liver disease (NAFLD) remain unclear. This study aimed to provide reliable estimates of ANA prevalence in subjects with biopsy-proven NAFLD and to investigate whether its associations with liver diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Ling, Ma, Qianqian, Lin, Limin, Wang, Hao, Ye, Junzhao, Zhong, Bihui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391168/
https://www.ncbi.nlm.nih.gov/pubmed/35990246
http://dx.doi.org/10.1155/2022/8446170
_version_ 1784770812962668544
author Luo, Ling
Ma, Qianqian
Lin, Limin
Wang, Hao
Ye, Junzhao
Zhong, Bihui
author_facet Luo, Ling
Ma, Qianqian
Lin, Limin
Wang, Hao
Ye, Junzhao
Zhong, Bihui
author_sort Luo, Ling
collection PubMed
description AIM: Associations between antinuclear antibodies (ANAs) and disease severity in nonalcoholic fatty liver disease (NAFLD) remain unclear. This study aimed to provide reliable estimates of ANA prevalence in subjects with biopsy-proven NAFLD and to investigate whether its associations with liver disease severity were established. METHODS: Observational studies measuring ANA in NAFLD patients were derived from the PubMed, Embase, and Web of Science databases from inception to March 30, 2022. The effect size was presented as the pooled risk difference, unstandardized mean differences (MDs), and odds ratio (OR) with a 95% confidence interval (CI). RESULTS: Thirteen articles involving 2331 patients were finally included. Among the subjects with biopsy-proven NAFLD, the overall prevalence of ANA positivity was high as 23% (95% CI: 19%-28%), but there were no statistically significant differences between ANA-positive and ANA-negative NAFLD patients in the levels of liver enzymes and blood lipids, grades of hepatocellular ballooning, lobular and portal inflammation, or risks of moderate-severe steatosis and significant fibrosis. However, the subgroup analysis showed that different geographic regions led to diverse results. ANA positivity was associated with a significantly elevated risk of significant fibrosis in the Eastern population (OR = 2.30, 95% CI: 1.30-4.06) but not in the Western population (OR = 1.00, 95% CI: 0.54-1.83). CONCLUSIONS: Serum ANA was present in approximately one-quarter of subjects with biopsy-proven NAFLD, but it conferred a greater risk of significant fibrosis only in Eastern but not Western populations.
format Online
Article
Text
id pubmed-9391168
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93911682022-08-20 Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis Luo, Ling Ma, Qianqian Lin, Limin Wang, Hao Ye, Junzhao Zhong, Bihui Dis Markers Review Article AIM: Associations between antinuclear antibodies (ANAs) and disease severity in nonalcoholic fatty liver disease (NAFLD) remain unclear. This study aimed to provide reliable estimates of ANA prevalence in subjects with biopsy-proven NAFLD and to investigate whether its associations with liver disease severity were established. METHODS: Observational studies measuring ANA in NAFLD patients were derived from the PubMed, Embase, and Web of Science databases from inception to March 30, 2022. The effect size was presented as the pooled risk difference, unstandardized mean differences (MDs), and odds ratio (OR) with a 95% confidence interval (CI). RESULTS: Thirteen articles involving 2331 patients were finally included. Among the subjects with biopsy-proven NAFLD, the overall prevalence of ANA positivity was high as 23% (95% CI: 19%-28%), but there were no statistically significant differences between ANA-positive and ANA-negative NAFLD patients in the levels of liver enzymes and blood lipids, grades of hepatocellular ballooning, lobular and portal inflammation, or risks of moderate-severe steatosis and significant fibrosis. However, the subgroup analysis showed that different geographic regions led to diverse results. ANA positivity was associated with a significantly elevated risk of significant fibrosis in the Eastern population (OR = 2.30, 95% CI: 1.30-4.06) but not in the Western population (OR = 1.00, 95% CI: 0.54-1.83). CONCLUSIONS: Serum ANA was present in approximately one-quarter of subjects with biopsy-proven NAFLD, but it conferred a greater risk of significant fibrosis only in Eastern but not Western populations. Hindawi 2022-08-12 /pmc/articles/PMC9391168/ /pubmed/35990246 http://dx.doi.org/10.1155/2022/8446170 Text en Copyright © 2022 Ling Luo et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Luo, Ling
Ma, Qianqian
Lin, Limin
Wang, Hao
Ye, Junzhao
Zhong, Bihui
Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
title Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
title_full Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
title_fullStr Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
title_full_unstemmed Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
title_short Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
title_sort prevalence and significance of antinuclear antibodies in biopsy-proven nonalcoholic fatty liver disease: a systematic review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391168/
https://www.ncbi.nlm.nih.gov/pubmed/35990246
http://dx.doi.org/10.1155/2022/8446170
work_keys_str_mv AT luoling prevalenceandsignificanceofantinuclearantibodiesinbiopsyprovennonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis
AT maqianqian prevalenceandsignificanceofantinuclearantibodiesinbiopsyprovennonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis
AT linlimin prevalenceandsignificanceofantinuclearantibodiesinbiopsyprovennonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis
AT wanghao prevalenceandsignificanceofantinuclearantibodiesinbiopsyprovennonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis
AT yejunzhao prevalenceandsignificanceofantinuclearantibodiesinbiopsyprovennonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis
AT zhongbihui prevalenceandsignificanceofantinuclearantibodiesinbiopsyprovennonalcoholicfattyliverdiseaseasystematicreviewandmetaanalysis